Pharma: Other News To Note
Monday, July 15, 2013
Actavis Inc., of Parsippany, N.J., said it received approval from the FDA on its abbreviated new drug application for oxymorphone hydrochloride extended-release tablets at dosages of 5 mg, 10 mg, 20 mg, 30 mg and 40 mg.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.